KR20240124925A - 아미노피라졸 화합물의 용도 - Google Patents

아미노피라졸 화합물의 용도 Download PDF

Info

Publication number
KR20240124925A
KR20240124925A KR1020247020622A KR20247020622A KR20240124925A KR 20240124925 A KR20240124925 A KR 20240124925A KR 1020247020622 A KR1020247020622 A KR 1020247020622A KR 20247020622 A KR20247020622 A KR 20247020622A KR 20240124925 A KR20240124925 A KR 20240124925A
Authority
KR
South Korea
Prior art keywords
compound
formula
compound according
dogs
jak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247020622A
Other languages
English (en)
Korean (ko)
Inventor
린다 호스풀
티모시 코왈스키
크리스티나 묄러
Original Assignee
인터벳 인터내셔널 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인터벳 인터내셔널 비.브이. filed Critical 인터벳 인터내셔널 비.브이.
Publication of KR20240124925A publication Critical patent/KR20240124925A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247020622A 2021-12-24 2022-12-23 아미노피라졸 화합물의 용도 Pending KR20240124925A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21217736 2021-12-24
EP21217736.4 2021-12-24
PCT/EP2022/087698 WO2023118555A1 (en) 2021-12-24 2022-12-23 Use of aminopyrazole compounds

Publications (1)

Publication Number Publication Date
KR20240124925A true KR20240124925A (ko) 2024-08-19

Family

ID=79025165

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247020622A Pending KR20240124925A (ko) 2021-12-24 2022-12-23 아미노피라졸 화합물의 용도

Country Status (9)

Country Link
US (1) US20250049775A1 (https=)
EP (1) EP4452970A1 (https=)
JP (1) JP2024545293A (https=)
KR (1) KR20240124925A (https=)
CN (1) CN118541364A (https=)
AU (1) AU2022418280A1 (https=)
CA (1) CA3242449A1 (https=)
MX (1) MX2024007863A (https=)
WO (1) WO2023118555A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286640B6 (sk) 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
KR101335843B1 (ko) 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-ｄ]피리미딘 화합물
CA2849168A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
WO2014146246A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
JP7116063B2 (ja) 2016-12-14 2022-08-09 インターベット インターナショナル ベー． フェー． 選択的ヤヌスキナーゼ阻害剤としてのアミノピラゾール類
KR20220119024A (ko) * 2019-12-20 2022-08-26 인터벳 인터내셔널 비.브이. 피라졸 제약 조성물

Also Published As

Publication number Publication date
WO2023118555A1 (en) 2023-06-29
EP4452970A1 (en) 2024-10-30
AU2022418280A1 (en) 2024-06-13
US20250049775A1 (en) 2025-02-13
CN118541364A (zh) 2024-08-23
JP2024545293A (ja) 2024-12-05
CA3242449A1 (en) 2023-06-29
MX2024007863A (es) 2024-08-30

Similar Documents

Publication Publication Date Title
JP2025092508A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
KR20050113163A (ko) 모다피닐의 제약 제제
JP6668045B2 (ja) ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
JP2020529995A (ja) 行動の変化の治療方法
WO2021016369A1 (en) Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
US20220117925A1 (en) Methods of treating or alleviating mental disorders and associated symptoms
US7989479B2 (en) Use of a p38 kinase inhibitor for treating psychiatric disorders
KR20240124925A (ko) 아미노피라졸 화합물의 용도
JP2022528520A (ja) プレガバリン製剤およびその使用
TWI864376B (zh) 焦慮症處置用組成物及處置方法
Cole et al. Treatment of equine nervous system disorders
Gruen et al. Drugs affecting animal behavior
CN108078984A (zh) 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用
US20190247405A1 (en) Treatment of sma
HK40122445A (en) Methods of treating behavior alterations
CN111432813A (zh) 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物
HK40119716A (zh) 利用替拉扎德盐治疗和预防疾病的组合物和方法
JP2024542831A (ja) Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途
HK40115079A (zh) 用於治疗汗腺炎的方法、剂量方案和组合物
HK40123938A (zh) 用於治疗X-ALD的甲状腺β激动剂给药方案
WO2020174238A1 (en) Prochlorperazine for the treatment of pitt-hopkins syndrome
Thomson Anti-Mediator Therapy
TW201919597A (zh) 利用新斯的明（neostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000